Research: Clinical parameters and novel serum biomarkers as surrogates of hepatic and extrahepatic impairment in patients with obesity and diabetes mellitus affected by Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Nutrition Biologist
Clinical research on obesity, type 1 and type 2 diabetes mellitus, insulin resistance, inflammation, and oxidative stress, with a focus on Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and liver fibrosis.
WORK EXPERIENCE:
- November 2023: PhD in Endocrinological Sciences, Department of Experimental Medicine - Sapienza University of Rome (in progress).
EDUCATION AND TRAINING:
- 2022-2023 Post-graduate Master in Dietetics and Clinical Nutrition (Istituto Alta Formazione, IAF, Rome)
- 2020-2022 Master's Degree in Food Sciences and Human Nutrition (LM-61), Class of degree in Sciences of Nutrition Human (LM-61), University of Perugia, Department of Pharmaceutical Sciences.
Degree grade: 110/110 cum laude with academic distinction
Thesis title: Metabolic resistance in obesity: focus on the FGF21-PPARGAMMA-ADIPONECTIN axis
Supervisor: Professor Michela Codini
-2016-2019 Bachelor's Degree in Food and Gastronomy Sciences (L-26), San Raffaele University, Rome (Uniroma 5)
Degree grade: 110/110 cum laude
Thesis title: Fake Food: the business of anonymity
Supervisor: Professor Alex Revelli Sorini
Co- Supervisor: Professor Susanna Cutini
-2008-2013 High School Diploma in Science, Chemical-Biological Adress-Levi Montalcini, Liceo Scientifico Ettore Majorana, Latina
Grade: 95/100
PROFESSIONAL QUALIFICATIONS, CERTIFICATIONS:
Professional Qualifications
- State Examination first Session 2022 with the achievement of the Qualification to practice as a Biologist – University of Bari
Grade: 10/10
- Registration with the Order of Biologists of Lazio and Abruzzo, 2023, Section A, No. 100018
Certifications
- Good Clinical Practice (ICH-GCP E6(R3)), 2025
- Use of FibroScan 530 (Transient Elastography), 2024
- Good Clinical Practice (ICH-GCP E6(R2)), 2024
CLINICAL TRIAL:
-Synchronize Trial¨- A Phase 3, randomised, double-blind, parallel-group, event driven, cardiovascular safety study with survodutide administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight related complications or risk factors for CVD
Role: Sub Investigator
CONFERENCE ABSTRACT PRESENTATION:
- “Weight Loss Effectiveness of Semaglutide in Real-World Obesity Management: Analysis by Liraglutide Switch, Sex, and Baseline BMI.” 33rd European Congress on Obesity - ECO 2026 - May 12-15, 2026
- “Real-world effectiveness and safety of semaglutide in obesity: early effects on weight loss and metabolic parameters.” 33rd European Congress on Obesity - ECO 2026 - May 12-15, 2026
- “Metabolic-associated fatty liver disease (MASLD): a growing comorbidity in type 1 diabetes.” Joint AMD-SID Lazio Congress- Diabetes Disease in 2025: Tradition, Innovation, and New Frontiers- October 24-25, 2025 - Rome
- "Diabetes and Obesity: The Renal Effects of GLP-1 Analogs" - SID-AMD Lazio Regional Congress - November 29-30, 2024 - Rome
- "Effects of Glucagon-like Peptide-1 Receptor Agonists on the Liver in Patients with Obesity and Type 2 Diabetes" - SID National Congress - October 23-26, 2024 - Rimini
- "Gender Difference in Response to Treatment with Liraglutide 3.0 mg" - 31st European Congress on Obesity - ECO 2024 - May 12-15, 2024
EDITORIAL ACTIVITY:
- Member of the editorial board of the Italian Society of Diabetes (SID)
PARTICIPATION IN RESEARCH PROJECTS:
- “Comparative effects of non-alcoholic fatty liver disease (NAFLD) and metabolic dysfunction-associated fatty liver disease (MAFLD) on risk of extra-hepatic complications”, PRIN: RESEARCH PROJECTS OF RELEVANT NATIONAL INTEREST - 2022 PNRR call;
- “Effect of weight loss obtained with semaglutide or sleeve gastrectomy on renal function in obese patients”, Ateneo Medio Project 2023.
CONTRIBUTIONS TO SCIENTIFIC JOURNALS:
- "Is bariatric surgery still a first-line option for the treatment of obesity?" - Il Diabete Online, Official Journal of the Italian Society of Diabetology (Obesity Updates, Vol. 37, No. 3, October 2025) - DOI: https://doi.org/10.30682/ildia2503e
- “An Unusual Type of Diabetes: “Not-1” and “Not-2”” - Il Diabete Online, Official Journal of the Italian Society of Diabetology (Clinical Update, Vol. 36, No. 3, October 2024) - DOI: https://doi.org/10.30682//ildia2403g